Literature DB >> 12699262

Medical management of endometriosis-associated pain.

Neal G Mahutte1, Aydin Arici.   

Abstract

In the coming years, basic science research into the mechanisms of endometriosis development and persistence almost certainly will open new avenues for treatment. A wide armamentarium of medical therapies already exists, however. The efficacy of most of these methods in reducing endometriosis-associated pain is well established. The choice of which to use depends largely on patient preference after an appropriate discussion of risks, side effects, and cost. Typically, oral contraceptives and NSAIDs are first-line therapy because of their low cost and mild side effects (Box 6). Because of its greater potential for suppressing endometrial development, consideration should be given to prescribing a low-dose monophasic oral contraceptive continuously. If adequate relief is not obtained or if side effects prove intolerable, consideration should be given to the use of progestins (oral, intramuscular, or IUD) or a GnRH agonist with immediate add-back therapy. Progestins are less expensive, but GnRH agonists with add-back may be better tolerated. If none of these medications proves beneficial or if side effects are too pronounced, then repeat surgery is warranted. The surgery may have analgesic value and serves to reconfirm the diagnosis. Finally, if endometriosis is identified at the time of surgery, then consideration should be given to prescribing medical therapy postoperatively.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12699262     DOI: 10.1016/s0889-8545(02)00057-8

Source DB:  PubMed          Journal:  Obstet Gynecol Clin North Am        ISSN: 0889-8545            Impact factor:   2.844


  12 in total

Review 1.  Managing the misplaced: approach to endometriosis.

Authors:  Bethany Jackson; Deanna E Telner
Journal:  Can Fam Physician       Date:  2006-11       Impact factor: 3.275

2.  Below the belt: approach to chronic pelvic pain.

Authors:  Risa Bordman; Bethany Jackson
Journal:  Can Fam Physician       Date:  2006-12       Impact factor: 3.275

3.  Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model.

Authors:  Jaime Kulak; Catha Fischer; Barry Komm; Hugh S Taylor
Journal:  Endocrinology       Date:  2011-05-17       Impact factor: 4.736

Review 4.  Pentoxifylline for the treatment of endometriosis-associated pain and infertility.

Authors:  Alexandros Loukas Grammatis; Ektoras X Georgiou; Christian M Becker
Journal:  Cochrane Database Syst Rev       Date:  2021-08-25

Review 5.  Gene therapy of benign gynecological diseases.

Authors:  Memy H Hassan; Essam E Othman; Daniela Hornung; Ayman Al-Hendy
Journal:  Adv Drug Deliv Rev       Date:  2009-05-13       Impact factor: 15.470

6.  Intestinal endometriosis mimicking carcinoma of rectum and sigmoid colon: a report of five cases.

Authors:  Jin Soo Kim; Hyuk Hur; Byung Soh Min; Hoguen Kim; Seung-Kook Sohn; Chang Hwan Cho; Nam Kyu Kim
Journal:  Yonsei Med J       Date:  2009-10-21       Impact factor: 2.759

7.  Treatment with bazedoxifene and conjugated estrogens results in regression of endometriosis in a murine model.

Authors:  Hanyia Naqvi; Sharif Sakr; Thomas Presti; Graciela Krikun; Barry Komm; Hugh S Taylor
Journal:  Biol Reprod       Date:  2014-04-16       Impact factor: 4.285

8.  Endometriosis presenting as carcinoma colon in a perimenopausal woman.

Authors:  Tanuja Muthyala; Pooja Sikka; Neelam Aggarwal; Vanita Suri; Rajesh Gupta; Uma Nahar
Journal:  J Midlife Health       Date:  2015 Jul-Sep

9.  Safety and tolerability of dienogest in endometriosis: pooled analysis from the European clinical study program.

Authors:  Thomas Strowitzki; Thomas Faustmann; Christoph Gerlinger; Ulrike Schumacher; Christiane Ahlers; Christian Seitz
Journal:  Int J Womens Health       Date:  2015-04-15

10.  A case of sigmoid endometriosis difficult to differentiate from colon cancer.

Authors:  Philippos Dimoulios; Ioannis E Koutroubakis; Maria Tzardi; Pavlos Antoniou; Ioannis M Matalliotakis; Elias A Kouroumalis
Journal:  BMC Gastroenterol       Date:  2003-08-07       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.